EUVIMEDEUVIMED entdecken
Multizentrische StudieKlinische Studie (Phase II)Open Access · CC BY-NC-ND 4.0

A Prospective, Multicenter, Open-Label, Single-Arm Phase 2 Study to Investigate the Pharmacokinetics, Safety, Tolerability, and Exploratory Efficacy of Selexipag in Children With Pulmonary Arterial Hypertension

Maurice Beghetti, Lene Nygaard Axelsen, Julian I Borissoff, Mahdi Farhan, Simon Grill, Sining Leng, Alberto Russu, Catherine Lesage, Tatiana Remeňová, Shu-Fang Hsu Schmitz, Shahin Moledina

CHEST · 2025

DOI: 10.1016/j.chest.2025.12.013 ↗

Kurz gefasst

Multizentrische Studie in der Zeitschrift CHEST, 2025. Verfasst von Maurice Beghetti und 10 weiteren Autor:innen. Beteiligte Einrichtung: Paediatric Cardiology Unit, University Hospitals of Geneva, Geneva, Switzerland. Hauptthemen laut MEDLINE: Pyrazines, Acetamides, Pulmonary Arterial Hypertension, Hypertension, Pulmonary. Die Arbeit nennt 35 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC-ND 4.0). Gefördert von: Johnson and Johnson, Johnson and Johnson Pharmaceutical Research and Development LLC.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

BACKGROUND: Selexipag is an oral selective prostacyclin receptor agonist approved for treating pulmonary arterial hypertension (PAH) in adults. RESEARCH QUESTION: What is the starting dose(s) of selexipag needed in patients ≥ 2 to < 18 years of age with PAH to achieve exposure comparable with adults (primary objective)? STUDY DESIGN AND METHODS: In this prospective, multicenter, open-label, single-arm, phase 2 study (NCT03492177), patients were categorized by age (≥ 2 to < 6, ≥ 6 to < 12, and ≥ 12 to < 18 years) and weight (≥ 9 to < 25, ≥ 25 to < 50, and ≥ 50 kg). Selexipag starting doses were based on patient body weight (≥ 50 kg: 200 μg bid; ≥ 25 to < 50 kg: 150 μg bid; and ≥ 9 to < 25 kg: 100 μg bid) and titrated to the individual maximum tolerated dose by week 12. The combined steady-state exposure to selexipag and its metabolite corrected for potency was assessed during titration. Safety, tolerability, and exploratory efficacy were assessed throughout the study; interim results (data cut off October 29, 2024) are reported. RESULTS: Sixty-three patients were enrolled and received selexipag. Most patients were prevalent, female (57%), with either idiopathic PAH (49%) or PAH associated with repaired or coincidental congenital heart disease (43%). The tested dosing regimen in the pediatric population demonstrated similar exposure to that observed in adults; the difference between the estimated and expected combined area under the plasma concentration-time curve over 1 dosing interval at steady state was < 25% in absolute value across age and body weight groups. Over a median of 230.3 weeks of treatment, 62 patients (98.4%) experienced ≥ 1 adverse event (AE) and 33 (52.4%) reported serious AEs. Most common AEs were vomiting (46.0%), headache (39.7%), and diarrhea (36.5%). Eleven (17.5%) deaths were reported; none were considered selexipag-related. Exploratory efficacy findings were consistent with those observed in adults. INTERPRETATION: These data support using a weight-based dosing regimen of selexipag in patients ≥ 2 to

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

PyrazinesAcetamidesPulmonary Arterial HypertensionHypertension, PulmonaryHumansFemaleMaleChildProspective StudiesAdolescentChild, PreschoolTreatment OutcomeAntihypertensive AgentsMaximum Tolerated DoseDose-Response Relationship, Drug

Stichwörter der Autor:innen

PAHefficacypediatricpharmacokineticssafetyselexipagweight-based dosing regimen

Substanzen

selexipagPyrazinesAcetamidesAntihypertensive Agents

Autor:innen und Institutionen

  • Paediatric Cardiology Unit, University Hospitals of Geneva, Geneva, Switzerland.
  • Johnson & Johnson, Allschwil, Switzerland.
  • Johnson & Johnson, Allschwil, Switzerland. Electronic address: JBorisso@its.jnj.com.
  • Johnson & Johnson, Milan, Italy.
  • Paediatric Cardiology, Great Ormond Street Hospital, London, England.

Förderung

  • Johnson and Johnson
  • Johnson and Johnson Pharmaceutical Research and Development LLC

Zitieren

APA

Beghetti, M., Axelsen, L. N., Borissoff, J. I., Farhan, M., Grill, S., Leng, S., Russu, A., Lesage, C., Remeňová, T., Hsu Schmitz, S. F., & Moledina, S. (2025). A Prospective, Multicenter, Open-Label, Single-Arm Phase 2 Study to Investigate the Pharmacokinetics, Safety, Tolerability, and Exploratory Efficacy of Selexipag in Children With Pulmonary Arterial Hypertension. CHEST. https://doi.org/10.1016/j.chest.2025.12.013

Vancouver

Beghetti M, Axelsen LN, Borissoff JI, Farhan M, Grill S, Leng S, et al. A Prospective, Multicenter, Open-Label, Single-Arm Phase 2 Study to Investigate the Pharmacokinetics, Safety, Tolerability, and Exploratory Efficacy of Selexipag in Children With Pulmonary Arterial Hypertension. CHEST. 2025. doi:10.1016/j.chest.2025.12.013

BibTeX
@article{Beghetti2025,
  author = {Beghetti, Maurice and Axelsen, Lene Nygaard and Borissoff, Julian I and Farhan, Mahdi and Grill, Simon and Leng, Sining and Russu, Alberto and Lesage, Catherine and Remeňová, Tatiana and Hsu Schmitz, Shu-Fang and Moledina, Shahin},
  title = {A Prospective, Multicenter, Open-Label, Single-Arm Phase 2 Study to Investigate the Pharmacokinetics, Safety, Tolerability, and Exploratory Efficacy of Selexipag in Children With Pulmonary Arterial Hypertension},
  journal = {CHEST},
  year = {2025},
  doi = {10.1016/j.chest.2025.12.013}
}
Kostenlos starten →